Gilead Stock News

If Gilead stock stays above 60 at expiry, the put expires worthless leaving the trader with a 36% annualized return.

Gilead Sciences Inc (NASDAQ: GILD ) announced new one-year results from the ongoing Phase 2/3 CAPELLA trial evaluating lenacapavir in heavily pretreated multi-drug resistant HIV patients. The findings demonstrated that lenacapavir, administered every six months in combination with other antiretrovirals, achieved high rates of virologic suppression. The data also showed clinically meaningful increases in CD4 counts in people … Full story available on Benzinga.com

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Amylyx's ALS Treatment Regulatory Application To Be Reviewed By FDA Panel In Late March Amylyx Pharma

Gilead Sciences Inc (NASDAQ: GILD) announced new one-year results from the ongoing Phase 2/3 CAPELLA trial evaluating lenacapavir in heavily pretreated multi-drug resistant HIV patients. The findin

Data from a phase 3 study on Gilead Sciences (GILD) lenacapavir given every six months in combination led to high rates of virologic suppression for treatment of HIV.

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced new one-year results from the ongoing Phase 2/3 CAPELLA trial evaluating lenacapavir, the company’s investigational, long-acting HIV-1 capsid inhibitor, in heavily treatment-experienced people living with multi-drug resistant HIV. The findings demonstrated that lenacapavir, administered subcutaneously every six months in combination with other antiretrovirals, achieved high rates of virologic suppression

US stocks traded lower midway through trading on Wednesday ahead of the release of Fed minutes. The Dow traded down 0.59% to 34,783.36 while the NASDAQ fell 0.92% to 14,009.57. The S&P also fell, dropping, 0.52% to 4,447.84. Check out this: Insiders Buy More Than $18M Of 4 Stocks Leading and Lagging Sectors Energy shares climbed 1.7% on Wednesday. Meanwhile, top gainers in the sector included NextDecade Corporation (NASDAQ: NEXT ), up 9% and Crescent Energy Company (NYSE: CRGY ) up 11%. In trading on Wednesday, information technology shares tumbled by 1.2%. Top Headline US crude-oil inventories gained 1.121 million barrels last week, the Energy Information Administration said. Analysts, however, were expecting for a 1.769-million-barrel decline in inventories. Equities Trading UP Upstart Holdings, Inc.. (NASDAQ: UPST ) shares shot up 36% to $148.09 after the company reported better-than-expected Q4 results and issued sales guidance above estimates. The company also announced a $400 million buyback.

Merger updates from BioDelivery (BDSI) and Seagen (SGEN) earnings results are among a few key highlights from the biotech sector during the past week.

Hookipa Pharma Inc (NASDAQ: HOOK) amended and restated collaboration and license agreement with Gilead Sciences Inc (NASDAQ: GILD) for arenaviral immunotherapy as a component of a potential funct

Hookipa Pharma Inc (NASDAQ: HOOK ) amended and restated collaboration and license agreement with Gilead Sciences Inc (NASDAQ: GILD ) for arenaviral immunotherapy as a component of a potential functional curative regimen for human immunodeficiency virus (HIV). In April 2018, Gilead licensed exclusive rights to Hookipa''s arenaviral platform to develop immunotherapies for HIV and hepatitis B virus (HBV). The companies agreed to … Full story available on Benzinga.com

Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Hookipa Gets $15M Upfront Payment And Equity Investment From Gilead Following Amended HIV Study Agreem

Why are investors unenthused with the biotech giant's earnings report?

Their long-term prospects appear to be bright.

Hookipa Pharma Inc (NASDAQ: HOOK) amended and restated collaboration and license agreement with Gilead Sciences Inc (NASDAQ: GILD) for arenaviral immunotherapy as a component of a potential funct